22 - 24 May 2017 - Boston
The Access and Life Science Strategy team from Pope Woodhead and Huron attended this year’s US ISPOR in Boston, and actively engaged in thought leadership activities, including a poster on orphan drug pricing and a white paper on value-based contracting in the US, as well as numerous interactions with payers, key opinion leaders and pharma / biotech clients.
Dominant themes of this year’s ISPOR included value-based contracting between payers and the pharma industry, as well as the increasing maturity of real world evidence (RWE) data collection and analytics.
During the three days, we had many discussions with existing and potential clients on value-based contracting and managed entry agreements (MEAs). Our proprietary MEA database and MEA financial modelling tools were very well received. We also saw growing interest in discussing our expertise in the commercialisation of new innovations (including cell/gene therapies and orphan drugs) and potential solutions going forward.
A huge thank you to all who stopped by the booth – we hope to see you all again soon
Click here view the poster
Click here to read the white paper